Gene Therapy Firm Freeline Successfully Tops Up Series C
CEO Says $120m Financing Will Advance Key Clinical Programs
An expanded $120m series C financing will help Freeline advance its lead program in hemophilia B into a pivotal trial next year, CEO Theresa Heggie tells Scrip.
